← Leaderboards
Andrew Zolopa
Stanford University
$11,147,487
Attributed
$11,147,487
Total exposure
49
Grants
35
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.7M · FY2005–14$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$11,147,487 · 49
By mechanism
U01$8,728,715 · 2
UM1$1,270,389 · 1
M01$1,148,383 · 46
Top collaborators
No co-investigators on record.
Most similar at Stanford University
Same institution · by research overlap
- Thomas N Robinson$40,790,008
- Tracey McLaughlin$5,362,409
- Brian Andrew Hargreaves$16,291,706
- Fredric B. Kraemer$7,721,140
- Joshua Wiley Knowles$7,436,668
Others in their field
Top investigators on “Resources”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$688,986,350
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Eric S Lander · Whitehead Institute For Biomedical Res$341,717,134
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$311,514,701
Research focus
ResourcesResearch PersonnelHiv InfectionsInstitutionFundingComputer Retrieval Of Information On Scientific Projects DatabaseGrantUnited States National Institutes Of HealthSourceAnti-Retroviral AgentsBaseInfectionRandomizedResponseHiv-1Acquired Immunodeficiency SyndromeDrug ResistanceAids Clinical Trial GroupMonitorClinical ResearchAids TherapyDrug ToxicityClinical Research SiteClinic
Grant awards (60)
Stanford AIDS Clinical Trials Unit$178,572
UM1 · FY2014 · AI · contact PI
Stanford AIDS Clinical Trials Unit$1,091,817
UM1 · FY2012 · AI · contact PI
Stanford AIDS Clinical Trials Unit$815,537
U01 · FY2011 · AI · contact PI
Stanford AIDS Clinical Trials Unit$856,218
U01 · FY2010 · AI · contact PI
Stanford AIDS Clinical Trials Unit$912,290
U01 · FY2009 · AI · contact PI
Stanford AIDS Clinical Trials Unit$816,602
U01 · FY2008 · AI · contact PI
CLINICAL TRIAL: FAT REDISTRIBUTION AND METABOLIC CHANGE IN HIV INFECTION: PROTOC$12,451
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: SUBJECTS ON POTENT ANTIRETROVIRAL THERAPY WITH PLASMA HIV-1 RNA$4,150
M01 · FY2008 · RR · contact PI
Stanford AIDS Clinical Trials Unit$867,835
U01 · FY2007 · AI · contact PI
A5211 STUDY OF THE SAFETY AND EFFICACY OF SHC417690 IN HIV-INFECTED SUBJECTS$123,246
M01 · FY2007 · RR · contact PI
ACTG 5001 ADULT AIDS CLINICAL TRIALS GROUP [ALLRT]$113,764
M01 · FY2007 · RR · contact PI
EFAVIRENZ OR ATAZANAVIR WITH RITONAVIR IN ANTIRETROVIRAL-NAIVE SUBJECTS (AIDS)$73,946
M01 · FY2007 · RR · contact PI
FAT REDISTRIBUTION AND METABOLIC CHANGE IN HIV INFECTION: PROTOCOL 2 (FRAM 2)$51,194
M01 · FY2007 · RR · contact PI
ATAZANAVIR AND RIFAMPIN IN HEALTHY HIV-SERONEGATIVE VOLUNTEERS$47,400
M01 · FY2007 · RR · contact PI
EZETIMIBE (ZETIA) IN COMBINATION WITH STATIN THERAPY IN HIV-INFECTED SUBJECTS$30,335
M01 · FY2007 · RR · contact PI
THE DE-ESCALATE STUDY: ATAZANAVIR OR ATAZANAVIR/RITONAVIR SUBSTITUTION IN HIV$30,335
M01 · FY2007 · RR · contact PI
SWITCH OF ANTIRETROVIRAL THERAPY BASED ON HIV RESISTANCE GENOTYPING$18,959
M01 · FY2007 · RR · contact PI
A5164: A PHASE IV STUDY OF ANTIRETROVIRAL THERAPY FOR HIV-INFECTED ADULTS$17,065
M01 · FY2007 · RR · contact PI
A5146 A RANDOMIZED-CONTROLLED TRIAL EVALUATING THE IMPACT OF TDM$11,376
M01 · FY2007 · RR · contact PI
A5157 AN OPEN-LABEL, DOSE-ESCALATION PILOT STUDY OF ACETYL-L-CARNITINE (AIDS)$7,582
M01 · FY2007 · RR · contact PI
A5142 A PHASE III, OPEN-LABEL COMPARISON OF LOPINAVIR/RITONAVIR (AIDS)$5,688
M01 · FY2007 · RR · contact PI
AIDS CLINICAL TRIALS UNIT$1,291,903
U01 · FY2006 · AI · contact PI
A5211: STUDY OF THE SAFETY AND EFFICACY OF SCH 417690 IN HIV-INFECTED SUBJECTS$95,400
M01 · FY2006 · RR · contact PI
ACTG 5001: THE ALLRT TRIALS$72,108
M01 · FY2006 · RR · contact PI
FAT REDISTRIBUTION AND METABOLIC CHANGE IN HIV INFECTION: PROTOCOL 2 (FRAM 2)$54,356
M01 · FY2006 · RR · contact PI
A5213: INTERACTIONS OF ATAZANAVIR AND RIFAMPIN IN HEALTHY HIV-1 VOLUNTEERS$28,844
M01 · FY2006 · RR · contact PI
STUDY OF INITIAL TREATMENT REGIMENTS IN PATIENTS WITH HIV INFECTIONS$26,624
M01 · FY2006 · RR · contact PI
ATAZANAVIR OR ATAZANAVIR/RITONAVIR SUBSTITUTION IN HIV-INFECTED INDIVIDUALS$21,076
M01 · FY2006 · RR · contact PI
ATAZANAVIR/RITONAVIR ALONE AS MAINTENANCE ANTIRETROVIRAL THERAPY IN HIV-1$18,860
M01 · FY2006 · RR · contact PI
ACTG 5223 SEX DIFFERENCES IN LOPINAVIR/RITONAVIR HIV-1-INFECTED MEN AND WOMEN$9,984
M01 · FY2006 · RR · contact PI
DIDEOXYNUCLEOSIDE-ASSOCIATED DISTAL SYMMETRIC PERIPHERAL NEUROPATHY IN AIDS$9,984
M01 · FY2006 · RR · contact PI
A5146 A HIV TRIAL EVALUATING THE IMPACT OF THERAPEUTIC DRUG MONITORING$5,548
M01 · FY2006 · RR · contact PI
A TRIAL OF VALGANCICLOVIR ACTG 5030 AIDS STUDY$4,436
M01 · FY2006 · RR · contact PI
A5164: A PHASE IV STUDY OF ANTIRETROVIRAL THERAPY FOR HIV-INFECTED ADULTS$3,328
M01 · FY2006 · RR · contact PI
PROTEASE INHIBITOR-SPARING REGIMENS FOR THE INITIAL TREATMENT OF HIV INFECTION$3,328
M01 · FY2006 · RR · contact PI
IMMUNIZATION WITH THE MRK AD5 HIV-1 GAG VACCINE IN HIV-1 INFECTED INDIVIDUALS$2,220
M01 · FY2006 · RR · contact PI
HIV SUBJECTS WHO DISCONTINUE ANTIRETROVIRAL THERAPIES$2,220
M01 · FY2006 · RR · contact PI
VIROLOGIC RELAPSE ON A CURRENT HAART REGIMEN$2,220
M01 · FY2006 · RR · contact PI
HIV THERAPY (HAART) WHO ARE NOT RESPONDING TO EITHER FISH OIL OR FENOFIBRATE$1,108
M01 · FY2006 · RR · contact PI
SWITCH OF ANTIRETROVIRAL THERAPY BASED ON HIV RESISTANCE GENOTYPING$1,108
M01 · FY2006 · RR · contact PI
AIDS CLINICAL TRIALS UNIT$1,559,846
U01 · FY2005 · AI
STUDY OF INITIAL TREATMENT REGIMENTS IN PATIENTS WITH HIV INFECTIONS$39,126
M01 · FY2005 · RR
HIV SUBJECTS WHO DISCONTINUE ANTIRETROVIRAL THERAPIES$10,956
M01 · FY2005 · RR
ATAZANAVIR OR ATAZANAVIR/RITONAVIR SUBSTITUTION IN HIV-INFECTED INDIVIDUALS$9,390
M01 · FY2005 · RR
VIROLOGIC RELAPSE ON A CURRENT HAART REGIMEN IN HIV PATIENTS$7,824
M01 · FY2005 · RR
ATAZANAVIR/RITONAVIR ALONE AS MAINTENANCE IN ANTIRETROVIRAL THERAPY IN HIV-1$3,129
M01 · FY2005 · RR
A5211: STUDY OF THE SAFETY AND EFFICACY OF SCH 417690 IN HIV-INFECTED SUBJECTS$3,129
M01 · FY2005 · RR
FAT REDISTRIBUTION AND METABOLIC CHANGE IN HIV INFECTION: PROTOCOL 2 (FRAM 2)$3,129
M01 · FY2005 · RR
A5164: A PHASE IV STUDY OF ANTIRETROVIRAL THERAPY FOR HIV-INFECTED ADULTS$3,129
M01 · FY2005 · RR
SWITCH OF ANTIRETROVIRAL THERAPY BASED ON HIV RESISTANCE GENOTYPING$3,129
M01 · FY2005 · RR
D-2-6-DIAMINOPURINE DIOXOLANE VS DAPD+MYCOPHENOLATE MOFETIL IN AIDS$1,571
M01 · FY2005 · RR
IMMUNIZATION WITH THE MRK AD5 HIV-1 GAG VACCINE IN HIV-1 INFECTED INDIVIDUALS$782
M01 · FY2005 · RR
DIDEOXYNUCLEOSIDE-ASSOCIATED DISTAL SYMMETRIC PERIPHERAL NEUROPATHY IN AIDS$782
M01 · FY2005 · RR
AIDS CLINICAL TRIALS UNIT$1,608,484
U01 · FY2004 · AI
Switch Of Antiretroviral Therapy Based on HIV Resistance Genotyping$16,268
M01 · FY2004 · RR
Fat Redistribution and Metabolism in HIV Patients[FRAM]$560
M01 · FY2004 · RR
A5164 A PHASE IV STUDY OF ANTIRETROVIRAL THERAPY FOR HIV$560
M01 · FY2004 · RR
NORVIRO (RITONAVIR) INDINAVIR THERAPY FOR HIV$134,676
M01 · FY2001 · RR
NORVIRO (RITONAVIR) INDINAVIR THERAPY FOR HIV$0
M01 · FY2001 · RR
NORVIRO (RITONAVIR) INDINAVIR THERAPY FOR HIV$0
M01 · FY2000 · RR